POCARED Diagnostics Ltd., an Israeli-based Diagnostics and Pre-analytical technology manufacturer with offices in the United States, announced they have closed another $15 Million round in funding.
The company boasts that it develops leading technology platforms that dramatically improve the ability of practitioners and hospitals to implement evidence-based medicine, while reducing lab operating costs and improving profitability. The funds raised will be used to complete its clinical trials and increase manufacturing capacity while preparing to commercialize both the POCARED P-1000TM and SP platforms.
The POCARED P-1000TM analysis platform offers direct- specimen, fully automated, reagent-free microorganism detection, Identification and enumeration, in minutes, by utilizing intrinsic fluorescence optical data. The SP, says the company, is the next-generation sample processor delivering second-to-none cell recovery, viability and robust fractionation capabilities. These technologies will be as an aid in the diagnosis of infectious diseases.
“These are exciting times for POCARED as we are closer to commercializing our first two platforms to make the POCARED revolution a reality” says Jonathan Gurfinkel, the company President and CEO. Mr. Gurfinkel goes on to say “The funding allows us to quickly build capacity in manufacturing and to begin development of further applications for the system.”
POCARED Diagnostics Ltd. is an in-vitro diagnostic company utilizing cutting edge technologies to develop next generation diagnostic and pre-analytical platforms. The company boasts that its CULTURE-FREE Microbiology is revolutionizing infectious disease diagnostics and practice with real-time results. The POCARED P-1000TM platform is fully automated, reagent-free, real-time and easy to operate. It provides multi-source detection, quantification and species identification for bacteria and yeast in a few minutes directly from the sample; saving several critical days in reporting compared to current practices. The SP is the next generation sample processing platform introducing second-to-none organism recovery, viability and robust fractionation capabilities. The SP is a general use, highly efficient rapid filtration-based, fractionation concentration platform. Biological particles, suspended in liquid-form are concentrated from a feed suspension. Cells of interest are detached, intact from the membrane using an innovative wet foam formulation.